AI‑powered biotech Earendil Labs secured $787 million in private financing to accelerate a sprawling biologics pipeline and build an R&D organization across the U.S. and China. Investors named in the round include Dimension and Luminous Ventures; Sanofi participated in prior partnerships and remains a collaborator. Earendil claims an AI platform producing more than 40 programs and plans to advance multiple candidates toward clinical testing, including one for inflammatory bowel disease now ready for Phase 2.